ARBITER 3 Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==ARBITER 3 Trial== ===Objective=== To study the effects of long term treatment with extended release niacin (ERN) on HDL l...") |
Rim Halaby (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To study the effects of long term treatment with extended release niacin (ERN) on [[HDL]] levels and carotid intima- media thickness in patients who participated in ARBITER 2. | To study the effects of long term treatment with extended release niacin (ERN) on [[HDL]] levels and carotid intima- media thickness in patients who participated in ARBITER 2. | ||
==Methods== | |||
88% (149) of patients enrolled in the ARBITER trial participated in the ARBITER 3 trial, those who either were continued or crossed over to the placebo group. The long term effects of ERN on HDL cholesterol and carotid intima- media thickness were examined during 12- 24 months of treatment. | 88% (149) of patients enrolled in the ARBITER trial participated in the ARBITER 3 trial, those who either were continued or crossed over to the placebo group. The long term effects of ERN on HDL cholesterol and carotid intima- media thickness were examined during 12- 24 months of treatment. | ||
==Results== | |||
* The ERN group showed an increase in [[HDL]]-C levels along with modest reductions in [[LDL]]-C and [[triglycerides]]. | * The ERN group showed an increase in [[HDL]]-C levels along with modest reductions in [[LDL]]-C and [[triglycerides]]. | ||
* A net regression in CMIT was seen in patients treated with ENC for 12 months. | * A net regression in CMIT was seen in patients treated with ENC for 12 months. | ||
| Line 16: | Line 16: | ||
* Changes in HDL-C were independently associated with regression of CIMT, controlling for changes in LDL and triglycerides. | * Changes in HDL-C were independently associated with regression of CIMT, controlling for changes in LDL and triglycerides. | ||
==Conclusion== | |||
ERN when added to statin therapy significantly increases HDL levels and induces [[atherosclerosis]] regression. Open label design and the inability to correlate CIMT effects to clinical outcomes were the limitations of this study.<ref name="pmid17076985">{{cite journal |author=Taylor AJ, Lee HJ, Sullenberger LE |title=The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 |journal=[[Current Medical Research and Opinion]] |volume=22 |issue=11 |pages=2243–50 |year=2006 |month=November |pmid=17076985 |doi=10.1185/030079906X148508 |url=}}</ref> | ERN when added to statin therapy significantly increases HDL levels and induces [[atherosclerosis]] regression. Open label design and the inability to correlate CIMT effects to clinical outcomes were the limitations of this study.<ref name="pmid17076985">{{cite journal |author=Taylor AJ, Lee HJ, Sullenberger LE |title=The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 |journal=[[Current Medical Research and Opinion]] |volume=22 |issue=11 |pages=2243–50 |year=2006 |month=November |pmid=17076985 |doi=10.1185/030079906X148508 |url=}}</ref> | ||
| Line 25: | Line 25: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
[[Category:HDLpedia]] | |||
Latest revision as of 14:31, 21 October 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ARBITER 3 Trial On the Web |
|
American Roentgen Ray Society Images of ARBITER 3 Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To study the effects of long term treatment with extended release niacin (ERN) on HDL levels and carotid intima- media thickness in patients who participated in ARBITER 2.
Methods
88% (149) of patients enrolled in the ARBITER trial participated in the ARBITER 3 trial, those who either were continued or crossed over to the placebo group. The long term effects of ERN on HDL cholesterol and carotid intima- media thickness were examined during 12- 24 months of treatment.
Results
- The ERN group showed an increase in HDL-C levels along with modest reductions in LDL-C and triglycerides.
- A net regression in CMIT was seen in patients treated with ENC for 12 months.
- An additional regression was noted in patients treated with ENC for 24 months.
- Changes in HDL-C were independently associated with regression of CIMT, controlling for changes in LDL and triglycerides.
Conclusion
ERN when added to statin therapy significantly increases HDL levels and induces atherosclerosis regression. Open label design and the inability to correlate CIMT effects to clinical outcomes were the limitations of this study.[1]
References
- ↑ Taylor AJ, Lee HJ, Sullenberger LE (2006). "The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3". Current Medical Research and Opinion. 22 (11): 2243–50. doi:10.1185/030079906X148508. PMID 17076985. Unknown parameter
|month=ignored (help)